Cover Image

市場進入的課題:黑色素瘤 (歐洲主要5個國家) (2018年)

Market Access Impact: Melanoma (EU5) 2018

出版商 FirstWord 商品編碼 488062
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:黑色素瘤 (歐洲主要5個國家) (2018年) Market Access Impact: Melanoma (EU5) 2018
出版日期: 2018年02月01日 內容資訊: 英文


本報告提供歐洲主要5個國家 (EU5:法國、義大利、德國、西班牙、英國)的150名癌症專門醫生、皮膚癌專門醫生為對象的黑色素瘤治療藥的領導品牌 (共8種)的處方趨勢,市場各種障礙的影響度的相關調查,市場障礙的概要 (共7項:價格,市場進入) ,其對各品牌市場佔有率和醫生的醫藥品選擇的影響度等分析。


  • 市場進入的各種障礙
    • 醫生最大量開立處方的品牌為何?
    • 受到各種障礙影響的處方箋數是多少?
    • 哪個障礙影響最大?
  • 各品牌的障礙的影響
    • 開立各品牌處方的醫生數是多少?未處方不過打算考慮數是多少?
    • 不開立處方的理由為何?其替代處方為何?
    • 各品牌的市場佔有率是多少?


  • Cotellic (Cobimetinib:Roche)
  • Imlygic (Talimogene laherparepvec:Amgen)
  • Keytruda (Pembrolizumab:Merck Sharp & Dohme)
  • Mekinist (Trametinib:Novartis)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Tafinlar (Dabrafenib:Novartis)
  • Yervoy (Ipilimumab:Bristol-Myers Squibb)
  • Zelboraf (Vemurafenib:Roche)


第1章 所謂市場障礙

第2章 本報告

第3章 關於本調查

第4章 調查中包含的品牌

第5章 摘要整理



Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out?

In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two rivals that are in 2nd and 3rd place. Find out how eliminating barriers would shake up the top and middle of the market, and help the last place brand double its share in Market Access Impact: Melanoma (EU5) [2018].

Based on a survey of 150 oncologists and dermato-oncologists, the report covers 8 major therapies from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways

  • Barriers affect a fifth of all prescriptions: But two barriers in particular affect more prescriptions than the others.
  • Market access is not the problem: Barriers related to market access affect far fewer prescriptions than either of the top two barriers.
  • Four brands gain share: But the most prescribed brand sees a significantly larger net gain than any other brand.
  • One brand loses big: The least-prescribed brand loses far more market share than any competitor, and suffers disproportionately from four of the seven barriers.
  • Eliminating barriers would shake up the rankings: Moving one brand into second place, shuffling the order in the middle of the pack, and doubling share for the last-place brand.
  • One brand has a big perception problem: Nearly 15% of surveyed doctors didn't even know it existed.

Insight into 8 Major Melanoma Drugs

  • Cotellic (cobimetinib; Roche)
  • Imlygic (talimogene laherparepvec; Amgen)
  • Keytruda (pembrolizumab; Merck Sharp & Dohme)
  • Mekinist (trametinib; Novartis)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tafinlar (dabrafenib; Novartis)
  • Yervoy (ipilimumab; Bristol-Myers Squibb)
  • Zelboraf (vemurafenib; Roche)

Market Access Impact: Melanoma (EU5) explores key issues affecting Melanoma drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists and dermato-oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world. All respondents have:

All respondents:

  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between January 10-23, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1. What are market barriers?

2. About this report

3. About the survey

4. Brands included in the survey

5. Executive summary

Back to Top